

# Eugeen Vanmechelen

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/6925112/eugeen-vanmechelen-publications-by-citations.pdf>

**Version:** 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

117 papers	10,344 citations	54 h-index	101 g-index
126 ext. papers	11,816 ext. citations	5 avg, IF	5.46 L-index

#	Paper	IF	Citations
117	Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. <i>Archives of Neurology</i> , <b>1999</b> , 56, 673-80		518
116	Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. <i>Journal of Neurochemistry</i> , <b>1993</b> , 61, 1828-34	6	423
115	Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. <i>Neuroscience Letters</i> , <b>2000</b> , 285, 49-52	3.3	397
114	Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice. <i>Archives of Neurology</i> , <b>2001</b> , 58, 373-9		372
113	Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. <i>Clinical Chemistry</i> , <b>2005</b> , 51, 336-45	5.5	358
112	Tau and Aβ42 in Cerebrospinal Fluid from Healthy Adults 21-83 Years of Age: Establishment of Reference Values. <i>Clinical Chemistry</i> , <b>2001</b> , 47, 1776-1781	5.5	351
111	Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. <i>Neuroscience Letters</i> , <b>2001</b> , 297, 187-90	3.3	347
110	Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. <i>Archives of Neurology</i> , <b>2010</b> , 67, 949-56		344
109	Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. <i>Archives of General Psychiatry</i> , <b>2004</b> , 61, 95-102		336
108	Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. <i>Archives of Neurology</i> , <b>2012</b> , 69, 1445-52		327
107	Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , <b>2000</b> , 7, 245-58	2.7	268
106	Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. <i>Biomarkers in Medicine</i> , <b>2012</b> , 6, 419-30	2.3	230
105	A Practical Guide to Immunoassay Method Validation. <i>Frontiers in Neurology</i> , <b>2015</b> , 6, 179	4.1	223
104	Cerebrospinal fluid tau and Aβ42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. <i>Neuroscience Letters</i> , <b>1999</b> , 273, 5-8	3.3	205
103	Evaluation of plasma Aβ40 and Aβ42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. <i>Neurobiology of Aging</i> , <b>2010</b> , 31, 357-67	5.6	197
102	Biochemistry of Tau in Alzheimer's disease and related neurological disorders. <i>Expert Review of Proteomics</i> , <b>2008</b> , 5, 207-24	4.2	197
101	CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. <i>Journal of Neural Transmission</i> , <b>2000</b> , 107, 563-79	4.3	194

100	CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease. <i>Molecular Neurobiology</i> , <b>2001</b> , 24, 87-97	6.2	186
99	Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias. <i>Molecular Psychiatry</i> , <b>2003</b> , 8, 343-7	15.1	182
98	Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. <i>Neurobiology of Aging</i> , <b>2008</b> , 29, 1143-59	5.6	181
97	Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach. <i>Journal of Neurochemistry</i> , <b>2003</b> , 85, 1581-91	6	176
96	Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?. <i>Neuroscience Letters</i> , <b>2009</b> , 450, 332-5	3.3	175
95	Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke. <i>Journal of Alzheimers Disease</i> , <b>2000</b> , 2, 199-206	4.3	160
94	Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease. <i>Brain Research</i> , <b>2010</b> , 1362, 13-22	3.7	156
93	Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds. <i>Dementia and Geriatric Cognitive Disorders</i> , <b>2003</b> , 15, 169-76	2.6	138
92	Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers. <i>Annals of Neurology</i> , <b>2005</b> , 58, 748-57	9.4	119
91	Nonfibrillar diffuse amyloid deposition due to a gamma(42)-secretase site mutation points to an essential role for N-truncated A beta(42) in Alzheimer's disease. <i>Human Molecular Genetics</i> , <b>2000</b> , 9, 2589-98	5.6	112
90	Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms. <i>Dementia and Geriatric Cognitive Disorders</i> , <b>2002</b> , 13, 112-8	2.6	110
89	Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment. <i>Acta Neurologica Scandinavica</i> , <b>2003</b> , 117, 47-51	3.8	107
88	The E Secretase BACE1 in Alzheimer's Disease. <i>Biological Psychiatry</i> , <b>2021</b> , 89, 745-756	7.9	107
87	Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years. <i>Journal of Alzheimers Disease</i> , <b>2007</b> , 12, 255-60	4.3	105
86	Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2006</b> , 44, 1472-80	5.9	100
85	C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease. <i>Alzheimers and Dementia</i> , <b>2015</b> , 11, 1461-1469	1.2	95
84	No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease. <i>Brain</i> , <b>2007</b> , 130, 2320-6	11.2	95
83	Evaluation of CSF biomarkers as predictors of Alzheimer's disease: a clinical follow-up study of 4.7 years. <i>Journal of Alzheimers Disease</i> , <b>2010</b> , 21, 1119-28	4.3	94

82	Plasma levels of beta-amyloid(1-40), beta-amyloid(1-42), and total beta-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins. <i>Archives of Neurology</i> , <b>2004</b> , 61, 333-7		94
81	Plasma amyloid $\beta$ 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease. <i>Alzheimers and Dementia</i> , <b>2019</b> , 15, 764-775	1.2	86
80	Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study. <i>Neurobiology of Aging</i> , <b>2008</b> , 29, 812-8	5.6	84
79	Identification of two-dimensionally separated human cerebrospinal fluid proteins by N-terminal sequencing, matrix-assisted laser desorption/ionization-mass spectrometry, nanoliquid chromatography-electrospray ionization-time of flight-mass spectrometry, and tandem mass spectrometry. <i>Electrophoresis</i> , <b>2000</b> , 21, 2266-83	3.6	84
78	Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology. <i>Acta Neuropathologica</i> , <b>2021</b> , 141, 709-724	14.3	83
77	The cerebrospinal fluid levels of tau, growth-associated protein-43 and soluble amyloid precursor protein correlate in Alzheimer's disease, reflecting a common pathophysiological process. <i>Dementia and Geriatric Cognitive Disorders</i> , <b>2001</b> , 12, 257-64	2.6	81
76	Identification of novel $\beta$ synuclein isoforms in human brain tissue by using an online nanoLC-ESI-FTICR-MS method. <i>Neurochemical Research</i> , <b>2011</b> , 36, 2029-42	4.6	74
75	Aberrant splicing in the presenilin-1 intron 4 mutation causes presenile Alzheimer's disease by increased Abeta42 secretion. <i>Human Molecular Genetics</i> , <b>1999</b> , 8, 1529-40	5.6	74
74	Amino-truncated beta-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment. <i>Clinical Chemistry</i> , <b>2005</b> , 51, 1650-60	5.5	73
73	Cerebrospinal beta-amyloid ((1-42)) in early Alzheimer's disease: association with apolipoprotein E genotype and cognitive decline. <i>Neuroscience Letters</i> , <b>2000</b> , 284, 85-8	3.3	70
72	An in vitro model for the study of microglia-induced neurodegeneration: involvement of nitric oxide and tumor necrosis factor-alpha. <i>Neurochemistry International</i> , <b>2001</b> , 38, 557-65	4.4	68
71	The utility of $\beta$ synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature. <i>Biomarkers in Medicine</i> , <b>2016</b> , 10, 19-34	2.3	67
70	Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's continuum when only subtle changes in A $\beta$ pathology are detected. <i>EMBO Molecular Medicine</i> , <b>2020</b> , 12, e12921	12	67
69	Phosphorylation of amyloid precursor carboxy-terminal fragments enhances their processing by a gamma-secretase-dependent mechanism. <i>Neurobiology of Disease</i> , <b>2005</b> , 20, 625-37	7.5	65
68	The effect of simvastatin treatment on the amyloid precursor protein and brain cholesterol metabolism in patients with Alzheimer's disease. <i>Dementia and Geriatric Cognitive Disorders</i> , <b>2005</b> , 19, 256-65	2.6	65
67	Low cerebrospinal fluid beta-amyloid 42 in patients with acute bacterial meningitis and normalization after treatment. <i>Neuroscience Letters</i> , <b>2001</b> , 314, 33-6	3.3	64
66	Characterization of tau in cerebrospinal fluid using mass spectrometry. <i>Journal of Proteome Research</i> , <b>2008</b> , 7, 2114-20	5.6	62
65	Tau as a biomarker of neurodegenerative diseases. <i>Biomarkers in Medicine</i> , <b>2008</b> , 2, 363-84	2.3	61

64	CSF markers for pathogenic processes in Alzheimer's disease: diagnostic implications and use in clinical neurochemistry. <i>Brain Research Bulletin</i> , <b>2003</b> , 61, 235-42	3.9	60
63	Increased CSF Synuclein levels in Alzheimer's disease: correlation with tau levels. <i>Alzheimers and Dementia</i> , <b>2014</b> , 10, S290-8	1.2	54
62	Added diagnostic value of CSF biomarkers in differential dementia diagnosis. <i>Neurobiology of Aging</i> , <b>2010</b> , 31, 1867-76	5.6	53
61	Postmortem changes in the phosphorylation state of tau-protein in the rat brain. <i>Neurobiology of Aging</i> , <b>1998</b> , 19, 535-43	5.6	49
60	Assessing the commutability of reference material formats for the harmonization of amyloid- $\beta$ measurements. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2016</b> , 54, 1177-91	5.9	48
59	Evidence that Abeta42 plasma levels in presenilin-1 mutation carriers do not allow for prediction of their clinical phenotype. <i>Neurobiology of Disease</i> , <b>1999</b> , 6, 280-7	7.5	48
58	Monitoring of $\beta$ amyloid dynamics after human traumatic brain injury. <i>Journal of Neurotrauma</i> , <b>2014</b> , 31, 42-55	5.4	47
57	Glycosylation of acetylcholinesterase and butyrylcholinesterase changes as a function of the duration of Alzheimer's disease. <i>Journal of Neuroscience Research</i> , <b>2003</b> , 72, 520-6	4.4	47
56	Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer's disease. <i>Alzheimers and Dementia: Translational Research and Clinical Interventions</i> , <b>2019</b> , 5, 871-882	6	45
55	Neurogranin and tau in cerebrospinal fluid and plasma of patients with acute ischemic stroke. <i>BMC Neurology</i> , <b>2017</b> , 17, 170	3.1	44
54	The Glu318Gly substitution in presenilin 1 is not causally related to Alzheimer disease. <i>American Journal of Human Genetics</i> , <b>1999</b> , 64, 290-2	11	43
53	The Cerebrospinal Fluid Neurogranin/BACE1 Ratio is a Potential Correlate of Cognitive Decline in Alzheimer's Disease. <i>Journal of Alzheimers Disease</i> , <b>2016</b> , 53, 1523-38	4.3	40
52	Cerebrospinal fluid tau and beta-amyloid(1-42) in dementia disorders. <i>Mechanisms of Ageing and Development</i> , <b>2001</b> , 122, 2005-11	5.6	39
51	Digital ELISA for the quantification of attomolar concentrations of Alzheimer's disease biomarker protein Tau in biological samples. <i>Analytica Chimica Acta</i> , <b>2018</b> , 1015, 74-81	6.6	37
50	Evaluation of plasma A $\beta$ as predictor of Alzheimer's disease in older individuals without dementia: a population-based study. <i>Journal of Alzheimers Disease</i> , <b>2012</b> , 28, 231-8	4.3	37
49	Evolution of Abeta42 and Abeta40 levels and Abeta42/Abeta40 ratio in plasma during progression of Alzheimer's disease: a multicenter assessment. <i>Journal of Nutrition, Health and Aging</i> , <b>2009</b> , 13, 205-8	5.2	37
48	The elusive tau molecular structures: can we translate the recent breakthroughs into new targets for intervention?. <i>Acta Neuropathologica Communications</i> , <b>2019</b> , 7, 31	7.3	35
47	Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia. <i>Journal of Alzheimers Disease</i> , <b>2013</b> , 33, 117-31	4.3	34

46	Generation and characterization of mouse microglial cell lines. <i>Journal of Neuroimmunology</i> , <b>1994</b> , 52, 153-64	3.5	33
45	Relevance of A $\beta$ 2/40 Ratio for Detection of Alzheimer Disease Pathology in Clinical Routine: The PLM Scale. <i>Frontiers in Aging Neuroscience</i> , <b>2018</b> , 10, 138	5.3	32
44	Microtubule-associated protein tau in human fibroblasts with the Swedish Alzheimer mutation. <i>Neuroscience Letters</i> , <b>1996</b> , 220, 9-12	3.3	31
43	Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study. <i>Neurobiology of Aging</i> , <b>2015</b> , 36, 2587-96	5.6	29
42	TDP-43 as a possible biomarker for frontotemporal lobar degeneration: a systematic review of existing antibodies. <i>Acta Neuropathologica Communications</i> , <b>2015</b> , 3, 15	7.3	29
41	Neurogranin as Cerebrospinal Fluid Biomarker for Alzheimer Disease: An Assay Comparison Study. <i>Clinical Chemistry</i> , <b>2018</b> , 64, 927-937	5.5	27
40	Developmental expression of tau proteins in the chicken and rat brain: rapid down-regulation of a paired helical filament epitope in the rat cerebral cortex coincides with the transition from immature to adult tau isoforms. <i>International Journal of Developmental Neuroscience</i> , <b>1995</b> , 13, 607-17	2.7	27
39	Tau immunoreactivity detected in human plasma, but no obvious increase in dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , <b>1999</b> , 10, 442-5	2.6	25
38	Analytical aspects of molecular Alzheimer's disease biomarkers. <i>Biomarkers in Medicine</i> , <b>2012</b> , 6, 377-89	2.3	24
37	Disease- and treatment-related elevation of the neurodegenerative marker tau in children with hematological malignancies. <i>Leukemia</i> , <b>2000</b> , 14, 2076-84	10.7	23
36	Association of CSF apolipoprotein E, Abeta42 and cognition in Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2002</b> , 23, 205-11	5.6	20
35	Growth-associated protein 43 in lesions and cerebrospinal fluid in multiple sclerosis. <i>Neuropathology and Applied Neurobiology</i> , <b>2006</b> , 32, 318-31	5.2	19
34	Cerebrospinal fluid neurogranin/Esite APP-cleaving enzyme 1 predicts cognitive decline in preclinical Alzheimer's disease. <i>Alzheimers and Dementia: Translational Research and Clinical Interventions</i> , <b>2018</b> , 4, 617-627	6	17
33	Tau monoclonal antibody generation based on humanized yeast models: impact on Tau oligomerization and diagnostics. <i>Journal of Biological Chemistry</i> , <b>2015</b> , 290, 4059-74	5.4	16
32	Neurotoxicity marker profiles in the CSF are not age-dependent but show variation in children treated for acute lymphoblastic leukemia. <i>NeuroToxicology</i> , <b>2004</b> , 25, 471-80	4.4	16
31	Neurogranin and BACE1 in CSF as Potential Biomarkers Differentiating Depression with Cognitive Deficits from Early Alzheimer's Disease: A Pilot Study. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , <b>2018</b> , 8, 277-289	2.5	16
30	Validation of soluble amyloid- $\beta$ precursor protein assays as diagnostic CSF biomarkers for neurodegenerative diseases. <i>Journal of Neurochemistry</i> , <b>2016</b> , 137, 112-21	6	15
29	Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231. <i>Alzheimers Research and Therapy</i> , <b>2021</b> , 13, 198	9	14



28	Unaltered plasma levels of beta-amyloid(1-40) and beta-amyloid(1-42) upon stimulation of human platelets. <i>Dementia and Geriatric Cognitive Disorders</i> , <b>2003</b> , 16, 93-7	2.6	12
27	Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease. <i>Alzheimers and Dementia</i> , <b>2021</b> ,	1.2	11
26	Association of Plasma A $\beta$ 0 Peptides, But Not A $\beta$ 2, with Coronary Artery Disease and Diabetes Mellitus. <i>Journal of Alzheimers Disease</i> , <b>2016</b> , 52, 161-9	4.3	10
25	Potential sources of interference on Abeta immunoassays in biological samples. <i>Alzheimers Research and Therapy</i> , <b>2012</b> , 4, 39	9	10
24	Functional mannose-binding lectin haplotype variants are associated with Alzheimer's disease. <i>Journal of Alzheimers Disease</i> , <b>2013</b> , 35, 121-7	4.3	10
23	Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays. <i>Neurology</i> , <b>2021</b> , 97, e1681-e1694	6.5	10
22	Brain A $\beta$ load association and sexual dimorphism of plasma BACE1 concentrations in cognitively normal individuals at risk for AD. <i>Alzheimers and Dementia</i> , <b>2019</b> , 15, 1274-1285	1.2	9
21	Pre-analytical stability of novel cerebrospinal fluid biomarkers. <i>Clinica Chimica Acta</i> , <b>2019</b> , 497, 204-211	6.2	8
20	A First Tetraplex Assay for the Simultaneous Quantification of Total $\beta$ Synuclein, Tau, $\beta$ Amyloid42 and DJ-1 in Human Cerebrospinal Fluid. <i>PLoS ONE</i> , <b>2016</b> , 11, e0153564	3.7	6
19	CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer's disease. <i>Alzheimers Research and Therapy</i> , <b>2020</b> , 12, 88	9	6
18	Critical Steps to be Taken into Consideration Before Quantification of $\beta$ Amyloid and Tau Isoforms in Blood can be Implemented in a Clinical Environment. <i>Neurology and Therapy</i> , <b>2019</b> , 8, 129-145	4.6	6
17	Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease.. <i>EBioMedicine</i> , <b>2022</b> , 76, 103836	8.8	4
16	Plasma $\beta$ Secretase1 concentrations correlate with basal forebrain atrophy and neurodegeneration in cognitively healthy individuals at risk for AD. <i>Alzheimers and Dementia</i> , <b>2021</b> , 17, 629-640	1.2	4
15	Plasma p-tau231, p-tau181, PET biomarkers and cognitive change in older adults.. <i>Annals of Neurology</i> , <b>2022</b> ,	9.4	3
14	Association of brain network dynamics with plasma biomarkers in subjective memory complainers. <i>Neurobiology of Aging</i> , <b>2020</b> , 88, 83-90	5.6	3
13	BACE1 and Other Alzheimer's-Related Biomarkers in Cerebrospinal Fluid and Plasma Distinguish Alzheimer's Disease Patients from Cognitively-Impaired Neurosyphilis Patients. <i>Journal of Alzheimers Disease</i> , <b>2020</b> , 77, 313-322	4.3	3
12	$\beta$ Secretase1 biological markers for Alzheimer's disease: state-of-art of validation and qualification. <i>Alzheimers Research and Therapy</i> , <b>2020</b> , 12, 130	9	2
11	Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease		2

10	Diagnostic value of serum versus plasma phospho-tau for Alzheimer's disease.. <i>Alzheimers Research and Therapy</i> , <b>2022</b> , 14, 65	9	2
9	Phospho-specific plasma p-tau181 assay detects clinical as well as asymptomatic Alzheimer's disease.. <i>Annals of Clinical and Translational Neurology</i> , <b>2022</b> ,	5.3	2
8	P4-232: A monoclonal antibody-based elisa for neurogranin <b>2015</b> , 11, P869-P869		1
7	Comparing tau status determined via plasma pTau181, pTau231 and [F]MK6240 tau-PET.. <i>EBioMedicine</i> , <b>2022</b> , 76, 103837	8.8	1
6	A Novel Tau Antibody Detecting the First Amino-Terminal Insert Reveals Conformational Differences Among Tau Isoforms. <i>Frontiers in Molecular Biosciences</i> , <b>2020</b> , 7, 48	5.6	0
5	Exploring molecular biomarkers with potential prognostic value in longitudinal observational studies on Alzheimer's disease. <i>Alzheimers and Dementia</i> , <b>2020</b> , 16, e047017	1.2	
4	P2-127: TDP-43 AS A BIOMARKER FOR FRONTOTEMPORAL LOBE DEGENERATION: A SYSTEMATIC REVIEW OF EXISTING ANTIBODIES <b>2014</b> , 10, P517-P518		
3	CSF Markers for Early Alzheimer's Disease275-283		
2	P1-251: CSF-NEUROGRANIN, BUT NOT BACE1, IS AN ALZHEIMER'S DISEASE SPECIFIC BIOMARKER <b>2018</b> , 14, P376-P376		
1	Cerebrospinal fluid neurogranin in Alzheimer's disease studies: are immunoassay results interchangeable?. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2022</b> , 60, e13-e17	5.9	